GTS Securities’s Arbutus Biopharma ABUS Stock Holding History

GTS Securities’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,100	Closed	-$46.6K	–	1243
2024 Q3	$46.6K	Buy	+12,100	New	+$46.4K	﹤0.01%	3902

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCP

BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GTS Securities's ABUS Position: Q4 2024 in Review

GTS Securities sold out of Arbutus Biopharma (ABUS) in Q4 2024, closing a stake of 28,817 shares — an estimated $111K sold.

GTS Securities first reported a position in ABUS in Q4 2023 and held it in 3 quarters. The position peaked at $129K in Q1 2024. 153 funds tracked by Wall St. Rank hold ABUS as of Q4 2024.

GTS Securities reported no remaining Arbutus Biopharma position as of Q4 2024 after selling out during the quarter.
GTS Securities sold 28,817 Arbutus Biopharma shares in Q4 2024, an estimated $111K.
GTS Securities first reported a position in Arbutus Biopharma in Q4 2023 and held it in 3 quarters.
GTS Securities's Arbutus Biopharma position peaked at $129K in Q1 2024.
153 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.